目的 探讨蒲苓盆炎康颗粒联合帕珠沙星治疗慢性盆腔炎的临床疗效。方法 选取2017年2月-2019年2月在武汉市东西湖区人民医院进行治疗的138例慢性盆腔炎患者，根据用药差别分为对照组和治疗组，每组各69例。对照组静脉滴注甲磺酸帕珠沙星氯化钠注射液，0.3 g/次，2次/d。治疗组患者在对照组基础上口服蒲苓盆炎康颗粒，10 g/次，3次/d。两组经2周治疗后进行效果比较。观察两组的临床疗效，比较两组治疗前后症状积分和血清学指标的变化情况。结果 治疗后，对照组和治疗组的总有效率分别是81.16%、97.10%，两组比较差异具有统计学意义（P<0.05）。治疗后，两组患者下腹腰骶疼痛评分、带下量多评分、带下色黄评分、发热评分、头晕耳鸣评分显著降低，同组治疗前后比较差异有统计学意义（P<0.05）；治疗后，治疗组这些症状评分显著低于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，两组血清C反应蛋白（CRP）、白细胞介素-6（IL-6）、肿瘤坏死因子-α（TNF-α）、血红素氧合酶1（HO-1）、细胞间黏附分子-1（ICAM-1）水平均较治疗前显著降低，同组治疗前后比较差异有统计学意义（P<0.05）；治疗后，治疗组这些血清学指标显著低于对照组，两组比较差异具有统计学意义（P<0.05）。结论 蒲苓盆炎康颗粒联合帕珠沙星治疗慢性盆腔炎具有较好的临床疗效，可有效改善患者临床症状，降低机体炎症反应，具有一定的临床推广应用价值。

Objective To explore the clinical efficacy of Puling Penyankang Granules combined with pazufloxacin mesylate in treatment of chronic pelvic inflammation. Methods Patients (138 cases) with chronic pelvic inflammation in Wuhan Dongxihu District People's Hospital from February 2017 to February 2019 were divided into control (69 cases) and treatment (69 cases) groups according to different medication regimens. Patients in the treatment group were iv administered with Pazufloxacin Mesylate and Sodium Chloride Injection, 0.3 g/time, twice daily. Patients in the treatment group were po administered with Puling Penyankang Granules on the basis of the control group, 10 g/time, three times daily. Patients in two groups were treated for 2 weeks. After treatment, the clinical efficacy was evaluated, and the changes of symptom scores and serological indicators in two groups were compared. Results After treatment, the clinical efficacy in the control and treatment groups were 81.16% and 97.10%, respectively, and there were differences between two groups (P<0.05). After treatment, lower abdominal lumbosacral pain score, subband quantity score, subband color yellow score, fever score, dizziness and tinnitus score were significantly decreased, and there were differences in the same group (P<0.05). After treatment, the symptom scores in the treatment group were lower than those in the control group, and there were differences between two groups (P<0.05). After treatment, the levels of CRP, IL-6, TNF-α, HO-1, and ICAM-1 in two groups were significantly decreased, and there were differences in the same group (P<0.05). After treatment, the serological indicators in the treatment group were lower than those in the control group, and there were differences between two groups (P<0.05). Conclusion Puling Penyankang Granules combined with pazufloxacin mesylate has significant effect in treatment of chronic pelvic inflammation, and can effectively improve the clinical symptoms of patients, and reduce the body's inflammatory response, which has a certain clinical application value.